CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

78 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaLey et al., 2010
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaPapaemmanuil et al., 2016
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaPonatinibGozgit et al., 2011
AFLT3ITD OR FLT3 D835 OR FLT3 I836PredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibPerl et al., 2019
BFLT3ITDPrognosticDoes Not SupportAcute Myeloid LeukemiaRibeiro et al., 2012
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGale et al., 2008
BFLT3ITDPrognosticDoes Not SupportAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2011
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaThiede et al., 2006
CFLT3ITD AND FLT3 D835YPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibMan et al., 2012
BFLT3TKD MUTATIONPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibZhang et al., 2008
BFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaLestaurtinibSmith et al., 2004
BFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSorafenibZhang et al., 2008
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaTyrphostin AG 1296Tse et al., 2002
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaWhitman et al., 2001
BFLT3TKD MUTATIONPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaWhitman et al., 2008
BFLT3D835PredictiveSupportsResistanceAcute Myeloid LeukemiaQuizartinib,SorafenibSmith et al., 2012
BFLT3D835PredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibMan et al., 2012
BFLT3ITDPredictiveSupportsResistanceAcute Promyelocytic LeukemiaAnthracycline Antineoplastic Antibiotic,TretinoinLucena-Araujo et al., 2014
DFLT3D835VPredictiveDoes Not SupportSensitivity/ResponseAcute Myeloid LeukemiaQuizartinibKampa-Schittenhelm et al., 2013
BFLT3MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibPerl et al., 2017
DFLT3ITDPredictiveSupportsSensitivity/ResponseLeukemiaSunitinib,SorafenibGozgit et al., 2011
DFLT3D835YPredictiveSupportsSensitivity/ResponseCancerGilteritinibMori et al., 2017
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibWilliams et al., 2013
DFLT3Y842CPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaLestaurtinibWilliams et al., 2013
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibMori et al., 2017
DFLT3D835YPredictiveSupportsSensitivity/ResponseLeukemiaLestaurtinibNguyen et al., 2017
BFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaTretinoinBurnett et al., 2010
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGale et al., 2008
DFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaDaunorubicinBagrintseva et al., 2005
DFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaSU5614Bagrintseva et al., 2005
BFLT3TKD MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaBacher et al., 2008
AFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaPort et al., 2014
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaLinch et al., 2014
BFLT3TKD MUTATIONDiagnosticDoes Not SupportPositiveAcute Myeloid LeukemiaYamamoto et al., 2001
BFLT3ITDDiagnosticSupportsPositiveAcute Myeloid LeukemiaYamamoto et al., 2001
BFLT3TKD MUTATIONPrognosticDoes Not SupportAcute Myeloid LeukemiaYamamoto et al., 2001
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaYamamoto et al., 2001
DFLT3D835PredictiveSupportsResistanceAcute Myeloid LeukemiaQuizartinib,PonatinibSmith et al., 2013
DFLT3D835PredictiveSupportsResistanceAcute Myeloid LeukemiaSU5614von Bubnoff et al., 2009
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Promyelocytic LeukemiaHong et al., 2011
BFLT3TKD MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinFischer et al., 2010
BFLT3T227MPredictiveSupportsAdverse ResponseRenal Cell CarcinomaSunitinibvan Erp et al., 2009
CFLT3OverexpressionPredictiveSupportsSensitivity/ResponseB-cell Adult Acute Lymphocytic LeukemiaSunitinibGriffith et al., 2016
CFLT3D835HPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibBaker et al., 2013
DFLT3D835VPredictiveSupportsResistanceAcute Myeloid LeukemiaTandutinibClark et al., 2004
DFLT3D835VPredictiveDoes Not SupportSensitivity/ResponseAcute Myeloid LeukemiaSunitinibYee et al., 2004
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaAS602868,Tyrphostin AG 1296Griessinger et al., 2007
Page 1 of 2
Next